Mexican women with family history more likely to have triple-negative breast cancer vs. other types
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of California San Diego Moores Cancer Center in La Jolla, California, have found that patients of Mexican descent with breast cancer who had a family history of breast or ovarian cancer were nearly two times as likely to have triple negative breast cancer than other types of breast cancer.
For the study, researchers identified 1,150 women of Mexican descent with breast cancer, 14.9% of whom reported having a first-degree relative with breast or ovarian cancer. They found that women with a first-degree relative who had one of those cancers were nearly twice as likely to be diagnosed with triple-negative breast cancer compared with other types of breast cancer.
The findings suggest that there will be implications in regard to prevention, screening, and treatment of women of Mexican descent with a family history of breast or ovarian cancer. Triple negative breast cancer is often associated with poor outcomes because it lacks the targets for common treatments.
Now, the researchers are investigating whether BRCA mutations are the cause of the association between family history and triple-negative breast cancer that was observed in this study.
Patients of Mexican descent with breast cancer and family history nearly two times as likely to have triple negative breast cancer.
Breast cancer patients of Mexican descent who had a family history of breast or ovarian cancer were almost twice as likely to have triple-negative breast cancer than other subtypes of breast cancer, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
"Triple-negative breast cancer is one of the worst breast cancer subtypes in terms of outcomes," said Maria Elena Martinez, PhD, the Sam M. Walton endowed chair for cancer research and a professor in the Department of Family and Preventive Medicine at the University of California San Diego Moores Cancer Center in La Jolla.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|